Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
Voravit Ratanatharathorn(University of Michigan–Ann Arbor), Steven Z. Pavletic(National Institutes of Health), Leo F. Verdonck(Isala), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Martin Bornhäuser(Technische Universität Dresden), Corey Cutler(Harvard University), H. Jean Khoury(Emory University), Joseph H. Antin(Dana-Farber Cancer Institute), Mukta Arora(Fairview Health Services), Stephen R. Spellman(National Marrow Donor Program), Vikas Gupta(Indian Institute of Technology Kanpur), Robert Peter Gale(Imperial College London), Dan Wang(Tianjin University of Traditional Chinese Medicine), Joseph P. Uberti(Sheba Medical Center), Mary Horowitz(Medical College of Wisconsin), Mitchell S. Cairo(New York Medical College), Gregory A. Hale(Johns Hopkins University), Olle Ringdén(Karolinska Institutet)
Cited by 71
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968